Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Innovative Medicine — Goodwill (Note 3)

Other segment segments

MEDTECH
$33.75B+0.6%

Similar metrics at other companies

Varex Imaging Corporation logo
VREXMedical — Goodwill
$173.5M—
Amneal Pharmaceuticals, Inc. logo
AMRXAffordable Medicines — Goodwill
$158.02M-2.3%
Gentherm logo
THRMMedical — Goodwill
$28.01M+3.3%
Adaptive Biotechnologies logo
ADPTImmune Medicine Business — Goodwill
$22.6M0.0%
Mirion Technologies logo
MIRMedical Segment — Goodwill
$634M0.0%
Opko Health logo
OPKPharmaceutical — Goodwill
$318.83M—

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — goodwill (note 3).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — goodwill (note 3)?
Johnson & Johnson (JNJ) reported innovative medicine — goodwill (note 3) of $14.81B in Q1 2026.
How has Johnson & Johnson's innovative medicine — goodwill (note 3) changed year-over-year?
Johnson & Johnson's innovative medicine — goodwill (note 3) increased by 35.8% year-over-year, from $10.91B to $14.81B.
What is the long-term trend for Johnson & Johnson's innovative medicine — goodwill (note 3)?
Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — goodwill (note 3) has grown at a 6.2% compound annual growth rate (CAGR), from $42.86B to $54.47B.
What does innovative medicine — goodwill (note 3) mean?
Represents the total carrying value of goodwill attributed to the Innovative Medicine operating segment as reported in financial notes. This reflects the premium paid over the fair value of net identifiable assets during past acquisitions within the pharmaceutical and biotechnology business. It serves as a measure of the intangible value and expected future synergies associated with the segment's portfolio.